BMS reports data for mAb against PD-1 receptor

Bristol-Myers Squibb Co. (NYSE:BMY) reported data from three cohorts of patients with advanced or recurrent malignancies in a Phase Ib trial of BMS-936558, a mAb against programmed cell death 1 ( PDCD1; PD-1; CD279). The trial enrolled 240 patients with melanoma, renal cell carcinoma (RCC), metastatic castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC) or colorectal cancer (CRC). ...